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Abstract
The acute-phase protein pentraxin-3 (PTX3) is a component of the innate immune system. Inflammation and tissue injury 
increased PTX3 in the injured liver, and accordingly, circulating PTX3 was induced in patients with chronic liver diseases. 
In the present study, PTX3 protein was determined in systemic, hepatic, and portal vein plasma of patients with liver cir-
rhosis to assess a possible association between hepatic PTX3 release and extent of liver injury. However, PTX3 levels were 
not related to disease severity. Of note, portal PTX3 levels were higher than concentrations in the hepatic vein. PTX3 in the 
hepatic and portal veins was negatively correlated with factor V, antithrombin 3, and prothrombin time. PTX3 did neither 
correlate with C-reactive protein nor galectin-3 or resistin, whereby the latter two proteins are associated with hepatic injury. 
PTX3 levels were not changed in cirrhosis patients with ascites or varices and did not correlate with the hepatic venous 
pressure gradient. Likewise, serum PTX3 was not correlated with histological steatosis, inflammation, or fibrosis stage in 
patients with hepatocellular carcinoma (HCC). Moreover, PTX3 was not associated with tumor node metastasis classifica-
tion in HCC. Above all, PTX3 increased in hepatic, portal, and systemic blood immediately after transjugular intrahepatic 
portosystemic shunt (TIPS). Higher PTX3 in portal than hepatic vein plasma and further increase after TIPS suggests that 
the liver eliminates PTX3 from the circulation. In summary, PTX3 is not of diagnostic value in cirrhosis and HCC patients.
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Introduction
Liver cirrhosis is the advanced stage of all chronic liver 
diseases [1]. Common complications are ascites, esopha-
geal varices, and renal impairment [2]. Portal hypertension 
accounts for these severe consequences [3]. Transjugular 
intrahepatic portosystemic shunt (TIPS) lowers portal pres-
sure and is a valuable option for the treatment of patients 
with refractory ascites and bleeding esophageal varices 
[4]. Adverse events of TIPS are hepatic encephalopathy 
[4] and thrombosis [5]. Liver tumors are considered a 
contraindication for TIPS, and this intervention was dis-
cussed to promote the onset of hepatocellular carcinoma 
(HCC) [6].
Pentraxin 3 (PTX3) is an acute-phase protein, and thus 
its expression is strongly induced in inflamed and injured 
tissues. Unlike C-reactive protein (CRP), which is primarily 
synthesized in hepatocytes, PTX3 secretion was increased 
in hepatic stellate cells, neutrophils, and monocytes [7]. 
Impaired hepatocyte function and accordingly CRP synthe-
sis limit the diagnostic value of CRP in patients with decom-
pensated liver cirrhosis [8]. PTX3 is a reliable marker for the 
activation of immune cells and was supposed to be superior 
to CRP in these patients [9].
PTX3 has an important function in tissue repair and 
wound healing. PTX3 deficiency was associated with 
increased clotting and fibrin deposition in line with a role 
of PTX3 in plasmin-mediated fibrinolysis [10, 11]. Hepatic 
stellate cells are the main cells responsible for tissue repair 
in the liver [12]. Accordingly, in experimental models of 
liver injury, PTX3 expression increased in these cells and 
contributed to enhanced synthesis of extracellular matrix 
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proteins like collagens. Moreover, hepatic inflammation and 
injury improved [11].
The prevalence of the metabolic syndrome, which is a 
risk factor for non-alcoholic fatty liver disease (NAFLD), 
is increasing. Plasma PTX3 was induced in patients with 
the metabolic syndrome. Of note, PTX3 was negatively cor-
related with high density lipoprotein [13]. A further study 
described a positive association of PTX3 mRNA expression 
in white blood cells with low-density lipoprotein [13, 14]. 
Accordingly, serum PTX3 was positively correlated with 
LDL-cholesterol in a cohort of type 2 diabetes patients [15]. 
Notably, type 2 diabetes patients with NAFLD had serum 
PTX3 levels as high as patients with normal liver function 
illustrating an association of serum PTX3 with dyslipidemia 
rather than NAFLD [13, 15]. Anyhow, a separate study 
described an association of plasma PTX3 with the stages 
of liver fibrosis in patients with NAFLD [16]. Moreover, 
PTX3 was strongly induced in alcoholic liver disease and 
was related to the model for end-stage liver disease (MELD) 
score. Plasma PTX3 was positively correlated with hepatic 
PTX3 gene expression indicating that the liver contributed 
to higher systemic levels [11]. In hepatitis C virus (HCV)-
infected patients, plasma PTX3 did not differentiate mild 
from severe fibrosis [17]. Accuracy of fibrosis assessment in 
HCV-infected patients was nevertheless improved by a score 
combining PTX3 levels, gamma-glutamyl transpeptidase/
platelet count ratio, hyaluronic acid, and age [18].
The prevailing opinion nowadays is that systemic PTX3 is 
induced in patients with chronic liver diseases [11, 19] and 
has a positive predictive value for adverse clinical outcomes 
[20, 21]. Liver cirrhosis is a risk factor for HCC, and PTX3 
may also have a role herein [17, 22].
Inflammation is a critical component of carcinogenesis 
and drugs which boost the anti-tumor immune response were 
successful in cancer therapy [23]. Genetic diversity of killer-
cell immunoglobulin-like receptor and human leukocyte 
antigen was related to the risk of HCV-related HCC further 
highlighting the role of the innate immune system in can-
cer [24]. Indeed, PTX3 facilitated progression of different 
cancers, and PTX3 expression in hepatocellular carcinoma 
(HCC) tissues was positively associated with shorter sur-
vival time of the patients [19]. Accordingly, plasma PTX3 
was high in HCC compared to patients with severe liver 
fibrosis [17]. Cancer-associated fibroblasts support tumor 
growth and metastatic disease. These cells were character-
ized by a high expression of profibrotic and proinflammatory 
genes and suppression of PTX3 [25]. PTX3 deficiency was 
linked to cancer-related inflammation, angiogenesis, and 
mutations in models of skin cancer [22]. Whether PTX3 
functions as a tumor-suppressor or tumor-promoting factor 
in HCC requires future work.
In this study, we hypothesized that induced PTX3 synthe-
sis in the cirrhotic liver results in higher PTX3 protein levels 
in the hepatic vein. Moreover, we postulated positive corre-
lations of hepatic vein PTX3 with measures of liver function 
in patients with liver cirrhosis and patients with HCC.
Materials and methods
Transjugular intrahepatic portosystemic shunt 
(TIPS)
The study included 35 patients with liver cirrhosis. Table 1 
lists the laboratory values of the patients. The etiology of 
liver cirrhosis was alcoholic in 30 patients, hepatitis C infec-
tion in 2 patients, and of other reasons in 3 patients. Tran-
sjugular intrahepatic portosystemic shunt (TIPS) (Viatorr-
Stent, Putzbrunn, Germany) implantation was done in the 
fasted state [26]. Complications requiring the insertion of 
the TIPS were variceal bleeding in 10 patients, hepatorenal 
syndrome in 1 patient, and refractory ascites in 24 patients. 
During this intervention, EDTA plasma of the hepatic vein 
(HVP), which was not drained by the TIPS stent, of the 
portal vein (PVP), and of a peripheral vein (SVP) was col-
lected. Blood samples were available from 35 (HVP), 34 
(PVP) and 26 (SVP) patients. Plasma was also obtained 
immediately after TIPS implantation, and HVP of 34, PVP 
of 35, and SVP of 34 patients were available for this study. 
Blood samples of these patients were used in previous stud-
ies [27, 28]. Routine laboratory parameters such as alanine 
aminotransferase and aspartate aminotransferase were meas-
ured by the Institute for Clinical Chemistry and Laboratory 
Medicine (University Hospital of Regensburg). The study 
was in accordance with the Declaration of Helsinki and was 
approved by the Ethical Committee of the University Hos-
pital of Regensburg. All patients provided written informed 
consent.
Hepatocellular carcinoma
Serum of 31 HCC patients was also available to measure 
PTX3. Details of the cohort are listed in Table 1 and were 
described in detail recently [29]. Experiments adhered to the 
guidelines of the charitable state controlled Human Tissue 
and Cell Research foundation. Ethical approval was obtained 
from the ethical committee of the Regensburg University 
Hospital. Each patient signed a written informed consent 
form.
Pentraxin‑3 ELISA
The human pentraxin-3 DuoSet ELISA was from R&D Sys-
tems and was performed as recommended by the company 
(Wiesbaden, Nordenstadt, Germany). Plasma was diluted 
1:2.5-fold for analysis.
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This ELISA was used in a previous study where serum 
was analyzed. The intra-assay coefficient of variation (CV) 
for the PTX3 ELISA was 5%, and the total CV for the assay 
was 7%. There was, however, no detailed information about 
the methods applied to evaluate this ELISA [30]. Mean 
serum PTX3 levels were about 2 ng/ml in that study cohort 
[30]. In the current analysis, median total % CV was 7.3%. 
For samples with PTX3 levels below 2 ng/ml, the % CV 
was 3.2, and for samples with PTX levels above 5 ng/ml, 
the % CV was 6.7%. Mean inter-assay % CV (5 samples in 
4 replicates) was 9.4%. These % CV values were within the 
recommended % CVs which are up to 10% for intra-assay 
and  up to 15% for intra-assay variations [31].
Fetal calf serum (two different batches) was analyzed as 
negative control (4 replicates on 4 different days). Values 
were always below the detection limit of the ELISA.
Recovery was determined by the use of recombinant 
PTX3 (provided by the company to be used in the standard 
curve). Here, 5.6, 2.2, and 0.9 ng protein were spiked into 
plasma of at least three different donors. The % recovery 
was 81, 79, and 88, respectively. This is almost within the 
acceptance range of 80–120% [32].
Statistics
Data are presented as box blots (IBM SPSS Statistics 25.0). 
Outliners were given as circles, (greater than 1.5 times 
the interquartile range) or stars (greater than 3.0 times the 
interquartile range). Statistical differences were analyzed 
by two-tailed Mann–Whitney U test. A p value < 0.05 was 
regarded as significant. Spearman correlation was calculated 
using the IBM SPSS Statistics 25.0 software.
Results
Pentraxin‑3 in serum of patients with liver cirrhosis
Thirty-five patients suffering from clinically diagnosed liver 
cirrhosis were enrolled in the study. Pentraxin-3 (PTX3) 
plasma concentrations were similar in both sexes (Fig. 1a). 
PTX3 did not correlate with the age of the patients (data 
not shown). Correlations were identified for systemic vein 
plasma (SVP) and portal vein plasma (PVP, r = 0.682, 
p < 0.001), SVP and hepatic vein plasma (HVP, r = 0.777, 
p < 0.001) and PVP and HVP PTX3 (r = 0.734, p < 0.001) 
(Fig. 1b, c and data not shown).
PTX3 was higher in PVP compared to HVP levels, which 
were similar to SVP concentrations (Fig. 1d). Indications 
for TIPS placement were mostly ascites and variceal bleed-
ing. Latter group had higher PTX3 in HVP and a trend to 
increased levels in PVP (p = 0.051) (Fig. 1e and data not 
shown).
Association with systemic inflammatory markers
PTX3 did not correlate with C-reactive protein (CRP) in 
the cirrhotic patients (Table 2). Moreover, there were no 
Table 1  Patient demographics 
and laboratory parameters
Median values and range of values were listed. Uppercase numbers were included when data were not 
available for the whole study group
CRP C-reactive protein, ALT alanine aminotransferase, AST aspartate aminotransferase
TIPS patients HCC patients p value
Number 35 31
Sex (female/male) 9/26 5/26
Age (years) 52 (40–81) 64 (33–85) 0.007
Child–Pugh stage A/B/C 9/12/14
MELD score 8 (6–21)
Ascites: no/little/modest/massive 4/9/3/19
Variceal size: no/small/large 6/7/22
C-reactive protein (mg/l) 13.4 (1.0–53.5)32
Fibrinogen (mg/dl) 310 (114–520)34
Antithrombin 3 (%) 64.4 (23.6–95.8)31
Factor V (%) 59 (17–137)25
ALT (U/l) 37 (4.0–108.0) 51 (17–378)29
AST (U/l) 29.0 (2.0–82.0) 37 (14–502)30
Albumin (g/l) 31.3 (1.6–47.0)
Bilirubin (mg/dl) 1.1 (0.3–8.2) 0.6 (0.2–2.5)30 < 0.001
Quick prothrombin time (%) 72 (28–100) 92 (76–100)23 < 0.001
Creatinine (mg/dl) 1.0 (0.5–4.5)
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associations of PTX3 with proteins released by immune 
cells which were measured in the serum of these patients 
before [28, 33]. Galectin-3 acts as a regulatory molecule in 
acute and chronic inflammation [34], but did not correlate 
with PTX3 (Table 2). Resistin is mainly synthesized by 
macrophages [35] and was not associated with PTX3 in 
HVP and PVP. Positive correlations of PTX3 and resistin 
were found in SVP (Fig. 1f, Table 2).
Fig. 1  PTX3 in plasma of 
patients with liver cirrhosis. 
a PTX3 levels in females (F) 
and males (M). b Correlation 
of portal vein plasma (PVP) 
and hepatic vein plasma (HVP) 
PTX3. c Correlation of HVP 
and systemic vein plasma 
(SVP) PTX3. d PTX3 in HVP, 
PVP, and SVP. e HVP PTX3 
in patients undergoing TIPS 
because of variceal bleeding or 
ascites. f Correlation of SVP 
PTX3 with resistin. *p < 0.05, 
***p < 0.001
Table 2  Correlation coefficients of PTX3 in the different blood com-
partments of cirrhosis patients with CRP measured in systemic blood, 
serum resistin, and serum galectin-3 measured in the respective blood 
compartments
Numbers in brackets indicate the number of patients where these data 
were available. *p < 0.05
PTX3 HVP PVP SVP
CRP (peripheral) 0.206 (32) 0.077 (31) 0.274 (25)
Resistin 0.236 (31) 0.208 (31) 0.418* (26)
Galectin-3 0.141 (31) 0.155 (31) 0.058 (26)
Fig. 2  Associations of PTX3 
with Child–Pugh and MELD 
score, creatinine clearance 
(CrCl), bilirubin, antithrombin 
3, and prothrombin time. a 
PTX3 in hepatic vein plasma 
(HVP) of patients stratified for 
Child–Pugh score. b Correlation 
of portal vein plasma (PVP) 
PTX3 with the MELD score. 
c PVP PTX3 in patients with 
normal and impaired (< 85 ml/
min) CrCl. d HVP PTX3 in 
patients with normal and high 
(≥ 1) bilirubin. e Correlation of 
PVP PTX3 with antithrombin 
3. f Correlation of PVP PTX3 
with quick prothrombin time. 
*p < 0.05, **p < 0.01
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Association of pentraxin‑3 with the severity of liver 
cirrhosis
PTX3 was similar in patients with compensated and 
decompensated liver cirrhosis (Fig. 2a). Accordingly, lev-
els in HVP, PVP, and SVP were not correlated with the 
MELD score (Fig. 2b and data not shown).
Associations with markers of hepatic and kidney 
function
There were no correlations of HVP, PVP, and SVP PTX3 
levels with albumin, aspartate aminotransferase, alanine 
aminotransferase, serum urea, creatinine, or creatinine clear-
ance (data not shown). Accordingly, PTX3 levels were simi-
lar in patients with normal (85–160 ml/min, 14 patients) and 
impaired (20 patients) creatinine clearance (Fig. 2c). Bili-
rubin was positively associated with HVP PTX3, and thus, 
PTX3 was higher in patients with bilirubin levels ≥ 1 mg/dl 
(Fig. 2d, Table 3).
Fibrinogen negatively correlated with HVP pentraxin-3 
(Table 3). Antithrombin 3 and factor V were negatively 
associated with HVP and PVP PTX3 (Fig. 2e, Table 3). 
Further, quick prothrombin time was negatively correlated 
with HVP and PVP PTX3 (Fig. 2f, Table 3). PVP and HVP 
PTX3 were lower in patients with normal prothrombin 
time (22/21 patients, respectively) compared to those 13 
patients with values ≤ 70% (prothrombin time > 70% is the 
normal range) (data not shown).
Ascites and varices
PTX3 was neither associated with ascites nor with variceal 
size (Fig. 3a, b). The hepatic venous pressure gradient 
(HVPG) is linked to the formation of ascites and varices 
[36] and was known from 33 patients. PTX3 in any blood 
compartment did not correlate with HVPG (Fig. 3c and 
data not shown).
PTX3 shortly after TIPS
PTX3 was also measured in the respective blood com-
partments immediately after TIPS. PTX3 levels were sig-
nificantly higher after stent insertion in portal, hepatic, 
and systemic venous plasma. Post-TIPS PTX3 was simi-
larly concentrated in all of these compartments (Fig. 3d). 
Increase in HVP PTX3 was 132.3 (86.8–220.0) % and 
was significantly higher than rise in PVP level, which was 
107.3 (80.0–179.3) % (p = 0.012). SVP increase was 122.5 
(72.9–182.8) % and was similar to changes in the two other 
blood compartments.
Table 3  Correlation coefficients of PTX3 in the different blood com-
partments of cirrhosis patients with bilirubin, prothrombin time, 
antithrombin 3, fibrinogen, and factor V analyzed in peripheral blood
Numbers in brackets indicate the number of patients where these data 
were available. *p < 0.05, **p < 0.01
PTX3 HVP PVP SVP
Bilirubin 0.447** (35) 0.196 (34) 0.141 (26)
Prothrombin time − 0.467** (35) − 0.528** (34) − 0.292 (26)
Antithrombin 3 − 0.543** (31) − 0.374* (30) − 0.226 (22)
Fibrinogen − 0.545** (34) − 0.328 (33) − 0.231 (25)
Factor V − 0.403* (25) − 0.489* (25) − 0.327 (20)
Fig. 3  Associations of PTX3 
with ascites, varices, and 
hepatic venous pressure 
gradient (HVPG, which is the 
gradient between pressures in 
the portal vein and the inferior 
vena cava) and levels of PTX3 
shortly after TIPS. a Portal vein 
plasma (PVP) PTX3 in patients 
without, little, modest and 
massive ascites. b PVP PTX3 in 
patients without, with small and 
large varices. c Correlation of 
portal vein plasma (PVP) PTX3 
ratio with HVPG. d PTX3 
in the three compartments 
before and shortly after TIPS. 
Significant higher level of PVP 
compared to HVP PTX3 before 
TIPS was not marked in this 
figure. **p < 0.01, ***p < 0.001
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After TIPS, antithrombin 3 was negatively associated 
with PTX3 in PVP (Table 4). Prothrombin time and factor 
V were negatively correlated with HVP and PVP PTX3 
levels (Table 4). Associations of post-TIPS PTX3 with 
fibrinogen and bilirubin did not exist (Table 4). PTX3 in 
any compartment after TIPS did not correlate with pre-
TIPS CRP, galectin-3, or resistin levels (data not shown).
PTX3 in patients with hepatocellular carcinoma
Liver cirrhosis is a risk factor for hepatocellular carci-
noma (HCC), which is a contraindication for TIPS [6]. 
In HCV-related HCC patients, PTX3 was high compared 
to non-cancer patients with mild or severe liver fibrosis 
[17]. Here, PTX3 was measured in serum of HCC patients 
where etiology was linked to NASH in 15 patients, hepa-
titis B infection in 3 patients, alcohol in 5 patients, and 
remained cryptic in 8 patients. Unfortunately, plasma was 
not available from this cohort. Measurement of plasma and 
serum from the same donor yielded higher values in serum 
[37]. Therefore, PTX3 levels of the HCC and cirrhosis 
patients could not be compared.
HCC patients were older and had lower bilirubin and 
improved prothrombin time than cirrhosis patients (Table 1). 
Serum PTX3 was not related to age, body mass index, or 
gender (data not shown). Moreover, there was no association 
of serum PTX3 with tumor node metastasis (TNM) clas-
sification in HCC patients (Fig. 4a). In the HCC cohort, 16 
patients had histology confirmed liver steatosis, 18 patients 
had liver inflammation, and 23 patients liver fibrosis. Serum 
PTX3 was not associated with any of these histological 
grades (Fig. 4b–d). Moreover, serum PTX3 was not related 
to bilirubin or prothrombin time (Fig. 4e, f).
Discussion
Main findings of the present study are that levels of PTX3 
(1) were higher in the portal as compared to the hepatic vein 
(2) and were increased after TIPS insertion. This suggested 
that the liver eliminates PTX3 from the blood.
PTX3 did not correlate with resistin and galectin-3, which 
are produced by immune cells [35]. Though circulating 
Table 4  Correlation coefficients of post-TIPs PTX3 in the different 
blood compartments with bilirubin, prothrombin time, antithrombin 
3, fibrinogen, and factor V
Numbers in brackets indicate the number of patients where these data 
were available. *p < 0.05, **p < 0.01
PTX3 HVP PVP SVP
Bilirubin 0.199 (34) 0.247 (35) 0.086 (34)
Prothrombin time − 0.361* (34) − 0.516** (35) − 0.270 (34)
Antithrombin 3 − 0.184 (30) − 0.365* (31) − 0.256 (30)
Fibrinogen − 0.204 (33) − 0.297 (34) − 0.206 (33)
Factor V − 0.398* (25) − 0.397* (25) − 0.311 (25)
Fig. 4  Serum PTX3 in HCC patients. a Correlation of PTX3 with 
TNM classification (TNM stage: IA/IB/IIA/IIB/III, number of 
patients 13/8/7/2/1). b PTX3 in patients stratified for hepatic steato-
sis (13 patients: no steatosis; 11 patients grade 1; 4 patients grade 2 
and 1 patient grade 3; steatosis grade of 2 patients was not known). 
c PTX3 in patients stratified for hepatic inflammation (4 patients: no 
inflammation; 17 patients grade 1 and 1 patient grade 2. Inflammation 
grade of 9 patients was not known). d PTX3 in patients stratified for 
hepatic fibrosis (8 patients: no fibrosis; 18 patients grade 1; 1 patient 
grade 2 and 4 patients grade 4). The number of patients in some 
subgroups was 1, and statistical test is not appropriate. e PTX3 in 
patients with normal and high (≥ 1) bilirubin. f Correlation of PTX3 
with Quick prothrombin time
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PTX3 in patients with liver cirrhosis was supposed as a 
marker of immune cell activation, high levels are also attrib-
uted to diminished hepatic excretion.
Negative correlations of PTX3 with prothrombin time 
were in accordance with a function of PTX3 in the extrin-
sic pathway of coagulation [38, 39]. Tissue factor initiates 
extrinsic blood coagulation and PTX3 enhanced the expres-
sion of this protein in activated monocytes and endothelial 
cells [38, 39]. Thus, shorter prothrombin time in cirrhotic 
patients with high PTX3 may be because of higher tissue 
factor expression.
PTX3 further negatively correlated with antithrombin 3, 
factor V, and fibrinogen. PTX3 indeed binds fibrinogen and 
enhances plasmin-induced fibrinolysis [10]. Thus, PTX3 
promotes fibrin deposition and fibrinolysis, and therefore, 
has a regulatory function in coagulation pathways [10, 
39]. Several pro- and anticoagulant factors are produced in 
the liver, and consequently, both pathways are impaired in 
patients with liver cirrhosis [40]. PTX3 was higher in cir-
rhotic patients than controls, whereas prothrombin conver-
sion as well as thrombin inactivation was impaired in these 
patients [21, 40]. This suggests that raised PTX3 in liver 
cirrhosis may in part compensate for deficiencies in pro- 
as well as anticoagulatory pathways. Correlations of PTX3 
with antithrombin 3 and factor V cannot provide informa-
tion on a functional association of these proteins nor does it 
prove whether PTX3 directly regulates the hepatic synthesis 
or the excretion of these proteins.
Negative correlations of PTX3 with fibrinogen and 
antithrombin 3 were also described in patients with acute 
Puumala hantavirus infection, a disease mainly character-
ized by renal dysfunction [41]. In contrast, such associa-
tions were not identified in patients with sickle cell painful 
crisis and women with preeclampsia [42, 43]. Additionally, 
serum PTX3 did not correlate with prothrombin time in 
HCC patients. Associations of PTX3 with measures of coag-
ulation were related to pathological condition, suggesting 
a complex regulatory network. PTX3 was correlated with 
inflammation, dyslipidemia, and renal function, illustrating 
that multiple influential factors are involved [7, 13, 14, 44].
PTX3 was not associated with the severity of liver dis-
ease defined by the Child–Pugh or MELD score in the 
cohort analyzed herein. A separate study described modest 
positive associations of PTX3 with these measures. Mean 
MELD score in that study was nearly twofold higher than 
of the patients enrolled in the present investigation. Indeed, 
patients with a MELD score over 20 had higher systemic 
PTX3 than patients with a lower score [21]. However, 
similar to our findings, PTX3 levels were not different in 
Child–Pugh class A, B, and C patients [21]. Hence, PTX3 
is not associated with the severity of liver disease. High lev-
els are more likely related to severe complications such as 
acute-on-chronic liver failure or infections [21].
This suggestion was supported as circulating PTX3 
showed no association with histological liver steatosis, 
inflammation, or fibrosis in patients with HCC. Of note, 
serum PTX3 did not increase with the TNM stages in liver 
cancer. This shows that high plasma PTX3 in HCC, which 
was even considered as a risk factor for HCC development 
[17], has no prognostic value.
In cirrhosis patients, PTX3 was neither related to 
ascites volume nor to variceal size. Moreover, PTX3 lev-
els were not induced in patients presenting with ascites or 
grades III/IV encephalopathy [21]. This excludes PTX3 as 
a marker of residual hepatic function and common compli-
cations of liver cirrhosis. PTX3 was, nevertheless, higher 
in patients with variceal bleeding compared to those with 
refractory ascites. These two cohorts had similar MELD 
score, prothrombin time, bilirubin, CRP, and resistin (data 
not shown). Related to the function of PTX3 in coagula-
tion, tissue injury was associated with higher local and 
systemic PTX3 in a skin-wounding model [10], and simi-
lar mechanisms may account for higher PTX3 in patients 
with variceal bleeding.
Moreover, pathological bacterial translocation is aggra-
vated in patients with variceal bleeding [45]. This boost of 
proinflammatory gut-derived mediators may further impact 
on PTX3 levels.
Interestingly, PTX3 was higher in the portal compared 
to the hepatic vein. PTX3 is mostly released by immune 
cells, and thus, the spleen and even bowel or omental adi-
pose tissue localized cells may contribute to portal vein 
PTX3. Median ratio of portal to hepatic vein PTX3 was 
117% in Child–Pugh A, 107% in Child–Pugh B, and 100% 
in Child–Pugh C patients. Though these values did not sig-
nificantly differ, they tend to decline in patients with more 
impaired hepatic function. PTX3 may be eliminated by the 
liver and impaired liver function may thus contribute to 
higher systemic levels. In line with this assumption, PTX3 
levels increased after TIPS. The more prominent rise of 
PTX3 in HVP compared to PVP shortly after TIPS further 
supports this hypothesis. A clinically interesting question 
is whether increased PTX3 shortly after this intervention 
contributes to higher thrombosis risk [5].
Post-TIPS PTX3 in the portal vein still correlated with 
prothrombin time, antithrombin 3, and factor V. In HVP, 
associations with prothrombin time and factor V persisted 
after TIPS. This principally points to a relatively strong 
association of PTX3 with coagulation. SVP PTX3 before 
and after TIPS showed now associations with coagulation 
factors or prothrombin time. This illustrates that, despite the 
high correlation of PTX3 levels among each of the blood 
compartments, additional mechanisms exist that specifically 
modulate its systemic concentration. Whether coagulation 
factor levels vary in the distinct blood compartments needs 
further analysis.
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There are limitations within our study. The cohort sizes 
were low, and effects were rather small. Plasma of HCC 
patients to analyze PTX3 was not available, and PTX3 lev-
els of the cohorts could not be compared.Moreover, MELD 
score of HCC patients was not documented.
In summary, the present study provides evidence that 
the liver eliminates PTX3 from the blood. Impaired hepatic 
removal of PTX3 in liver cirrhosis may contribute to 
increased plasma levels. Anyhow, circulating PTX3 is not 
of prognostic value in liver cirrhosis or HCC.
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